The Maryland company, which has a $1.75 billion federal contract to develop and produce a coronavirus vaccine, said it needed to address the concerns of federal regulators.
Novavax, the Maryland firm that won a $1.75 billion federal contract to develop and produce a coronavirus vaccine, said on Thursday that the federal government would not fund further production of its vaccine until the company resolves concerns of federal regulators about its work. The firm’s disclosure came in a quarterly filing with the Securities and Exchange Commission. The Trump administration agreed to buy 110 million doses of vaccine from Novavax as part of its crash vaccine development program. Although the company reported in June that its vaccine had an efficacy of 90 percent against symptomatic Covid-19 cases, and 100 percent against severe disease, Novavax has struggled for months to mass manufacture its product. Its vaccine has not been authorized for distribution in the United States, and federal officials said it is unclear when or if it will be.
